FLLL32, a curcumin analog, ameliorates intestinal injury in necrotizing enterocolitis

Jeffrey Eckert¹
Brian Scott¹,²
Shelley M Lawrence³
Michael Ihnat⁴
Hala Chaaban¹

¹Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Department of Pediatrics, University of Texas Health Science Center at San Antonio, San Antonio, TX, ³Department of Pediatrics, University of California San Diego, San Diego, CA, ⁴Department of Pharmaceutical Sciences, University of Oklahoma, College of Pharmacy, Oklahoma City, OK, USA

Introduction

Necrotizing enterocolitis (NEC) is a devastating gastrointestinal disease characterized by inflammation and injury to the small intestine.¹,² Despite advances in care, NEC remains the leading cause of morbidity and mortality in infants born weighing less than 1500 g.³,⁴ Although the etiology of NEC is unclear, evidence suggests that inflammation plays a central part in the pathogenesis.⁵,⁶ Specifically, activation of Toll-like receptor 4 (TLR4) is essential for the development of NEC.⁷–⁹ Thus, strategies to inhibit TLR activation or inflammatory cytokines have been proposed to help ameliorate injury in models of NEC.¹⁰,¹¹

Curcumin is a natural compound found in Curcuma longa.¹² Curcumin interacts with numerous targets that are involved in inflammation.¹²–¹⁵ It downregulates inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin (IL)-1, IL-6, and IL-8, by inhibiting TLR4/nuclear factor kappa B (NF-κB) activation.¹⁴,¹⁵ In intestinal inflammation models, curcumin attenuates inflammation and injury through inhibition of COX-2 expression¹⁶ and the Janus kinase (JAK)/signal transducers and activators of transcription (STAT) signaling pathways.¹⁷–²⁰

The safety and tolerability of curcumin at high doses are well established. However, under physiologic conditions, curcumin is unstable and has poor bioavailability. FLLL32 is a diketone analog of curcumin that exhibits improved potency and biochemical
properties, specifically as an inhibitor of the inflammatory signaling molecule Jak2/STAT3. The use of FLLL32 in intestinal inflammation has not been explored. Thus, the purpose of this study was to determine the effect of FLLL32 in a neonatal NEC-like intestinal inflammation model.

**Methods**

**Effect of FLLL32 and curcumin on IL-6-induced reduction of transepithelial electrical resistance (TEER) in T84 monolayer**

T84 intestinal epithelial cells (CCL-248) purchased from the American Type Cell Culture (ATCC, Manassas, VA, USA) were grown under standard conditions as described previously. Cells were seeded in 24-well Transwells (Cat#: 353495, 6.5 mm diameter, 0.4 mm pore size, PET track-etched membrane) at a density of $6 \times 10^4$ cells/800 mL/well (BD Biosciences, San Jose, CA, USA). Cells were grown for 7 days on the Transwells prior to the experiments, until TEER indicated established tight junction formation.

**Determination of no-observable-adverse-effect-level (NOAEL)**

To determine the safety and tolerability of FLLL32 (Calbiochem®) in neonatal mice, P8-P14 CD-1 mouse pups were orally gavaged 25 and 50 mg/kg of FLLL32 at a volume of 10 µL/g once daily at the same time every day for 7 days. The pups were weighed daily and observed for any adverse effects, such as lethargy, abnormal behavior, weight loss, and death.

**Experimental model of NEC**

All animal procedures were approved by the Institutional Animal Care and Use Committee at the University of Oklahoma Health Sciences Center and were performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals. Briefly, CD-1 (Charles River Laboratory) pups were divided into three groups: 1) Sham (n=6), 2) NEC (n=18), and 3) NEC + FLLL32 (n=12). The NEC + FLLL32 group received 25 mg/kg of FLLL32 by oral gavage from P9 to P14. This was based on prior studies and the NOAEL effects listed previously. NEC was induced at P15 using the Paneth-cell ablation and *Klebsiella* infection model, also known as the dithizone/*Klebsiella* model (DK model). Pups received an intraperitoneal (ip) injection of 33 mg/kg of dithizone (Sigma-Aldrich, St. Louis, MO, USA) or an equivalent volume of vehicle alone at P15. Six hours after the injection, mice pups received an enteral gavage of $10^8$ CFU/g body weight *Klebsiella pneumoniae* (ATCC#10031, Manassas, VA, USA). Mice pups were then continuously monitored for 10 hours after which they were euthanized, and blood and tissues were collected.

**Histological evaluation of NEC**

Tissues were fixed with 10% formalin buffer and stained with hematoxylin and eosin for microscopic examination. Mucosal injury was evaluated by two blinded pathologists and graded on a 4-point scale: grade 0, no injury (normal); grade 1, separation of the villous core; grade 2, villous core separation and epithelial sloughing; and grade 3, denudation of epithelium with loss of villi, full-thickness necrosis. The analysis was performed on three to five sections. Animals with histological scores ≥2 were defined as having NEC.

**In vivo intestinal barrier function assay**

To investigate the effect of FLLL32 on intestinal permeability barrier function in the NEC model, an in vivo permeability assay was performed using fluorescein isothiocyanate (FITC)-dextran. Surviving mice pups were gavaged 4 kDa FITC-dextran (44 mg/100 g body weight). After 4 hours, blood was collected and centrifuged at 4°C, 3000 g for 10 min. Plasma was diluted in an equal volume of phosphate-buffered saline (PBS) and analyzed for DX-4000–FITC concentration with a fluorescence spectrophotometer (Tecan, Maennedorf, Switzerland) at an excitation wavelength of 480 nm and emission wavelength of 520 nm.

**Mouse inflammatory cytokine quantification**

Small intestinal samples were homogenized in lysis buffer. Intestinal cytokines were analyzed using custom designed Procarta Plex Mouse Cytokine & Chemokine Panel 1A (eBioscience, San Diego, CA, USA) as per manufacturer instructions. Final cytokine levels were normalized to total protein concentration (milligram/milliliter) and reported as picogram/microgram protein.
Statistical analysis
Data are presented as mean ± standard error of mean (SEM) and analyzed using one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test. Data were considered significant when \( p < 0.05 \). All the analyses were performed using GraphPad Prism version 6.00 for Windows (GraphPad Software, La Jolla, CA, USA).

Results
FLLL32 protects T84 monolayers against inflammation-induced paracellular permeability
To evaluate the effect of FLLL32 on intestinal permeability in vitro, we measured the TEER in T84 cell monolayers. Similar to previous studies,24 IL-6 decreased the TEER in a time-dependent manner, indicating increased tight junction permeability to ionic solutes. As seen in Figure 1, the addition of 10 mg/mL IL-6 to the culture medium for 72 hours induced more than 25% decrease in the TEER reading compared to baseline in a time-dependent manner. Pretreatment with FLLL32 ameliorated IL-6 effect on TEER at 24, 48, and 72 hours (Figure 1). In contrast to curcumin pretreatment, at the same molar concentration, FLLL32 had no effect on IL-6-induced reduction in TEER at 24 and 48 hours. At 72 hours, a modest alleviation on TEER is seen when compared with FLLL32 pretreatment. These results could suggest that FLLL32 is more superior to curcumin in preserving barrier function in vitro compared to curcumin.

Determination of NOAEL
Although the use of FLLL32 has been used extensively in different murine models of malignancy, its use in neonatal mice pups has not been reported. Thus, we sought to determine its safety and tolerability in CD-1 mice pups for 7 days starting P8 till P 14. We administered FLLL32 orally at two different doses, 25 mg/kg and orally 50 mg/kg at a volume of 10 µL/g once daily. The pups were weighed daily and observed for any clinical signs of distress such as lethargy, abnormal behavior, weight loss, or death. Pups receiving 25 mg/kg of FLLL32 had no clinical signs of adverse events and had no difference in weight gain compared to controls. In contrast, pups receiving 50 mg/kg daily had lower weight gain on days 6 and 7 compared to both control and the 25 mg/kg group (Figure 2).

FLLL32 reduces incidence and severity of intestinal injury in DK NEC model
NEC was induced using the DK NEC model as described in the “Methods” section. Figure 3A–C shows representative histological pictures of sections obtained from the three groups. As expected, sham pups had normal villi and submucosal structure (Figure 3A). The untreated NEC group

Figure 1 Effect of FLLL32 and curcumin on IL-6-induced reduction of TEER in T84 monolayer.
Notes: TEER value of T84 monolayers incubated with cell culture medium for 0–72 hours in the presence of IL-6 (10 ng/mL) with FLLL32 (50 µM), curcumin (50 µM), or carrier (dimethyl sulfoxide) for 1 hour in serum-free medium. ***p=0.001 (IL-6 vs. IL-6 + FLLL32 at 24 hours), ****p=0.0001 (IL-6 vs. IL-6 + FLLL32 at 48 and 72 hours), and #p=0.003 (IL-6 vs. IL-6 + curcumin).
Abbreviations: IL, interleukin; TEER, transepithelial electrical resistance.
had moderate to severe intestinal villi damage (Figure 3B). More importantly, pups in the NEC + FLLL32 had mild evidence of intestinal injury (Figure 3C). To further determine the incidence and severity of NEC in the groups, we used the modified NEC scoring system.26 Pretreatment with FLLL32 reduced intestinal injury score from a mean of 2 in the untreated group to a mean of 0.33 in the NEC + FLLL32 group (Figure 3D). In addition, the FLLL32 reduced the incidence of NEC from 72% (13/18) in the untreated NEC group (Figure 3D). In addition, the FLLL32 reduced the incidence of NEC from 72% (13/18) in the untreated NEC group to 8% (1/12) in the treated group (p=0.001).

**FLLL32 protects intestinal barrier in a DK NEC model**

Although the etiology of NEC remains incompletely understood, evidence shows that breakdown of the intestinal barrier is a predisposing factor in the development of NEC.9,29-31 To determine whether FLLL32 protection against NEC was associated with preservation of intestinal barrier, intestinal permeability was assessed by oral administration of the FITC-dextran (4 kDa) to all surviving pups. Concentrations of FITC-dextran in serum were measured 4 hours after administration. As shown in Figure 3E, the sham group had low FITC-dextran levels in the blood. Pups in the untreated NEC group had the highest levels of FITC-dextran in the blood, reflecting increased intestinal permeability. Pups in NEC + FLLL32 group had significantly decreased FITC-dextran in blood to near sham levels, indicating that pretreatment with FLLL32 protected intestinal barrier (p<0.0001).

**FLLL32 decreases intestinal inflammatory cytokine protein levels in DK NEC model**

Consistent evidence demonstrates the important role of inflammatory cytokines in the pathogenesis of NEC.5,9-32 To determine the effect of FLLL32 on intestinal cytokine levels, we compared the levels of IL-1β, IL-6, growth-regulated oncogene-alpha (GRO-α), and TNF-α in intestinal tissue lysates from pups in the three groups. Similar to other studies,21 levels of all inflammatory cytokines were significantly increased compared to sham (Figure 3F–I). Interestingly, pups in the NEC + FLLL32 group resulted in 2.5-fold decrease in TNF-α (Figure 3F, p=0.001), 5.8-fold decrease in IL-6 (Figure 3G, p<0.001), 4.8-fold decrease in IL-1β (Figure 3H, p=0.009), and 5-fold decrease in GRO-α levels (Figure 3I, p=0.034) compared to pups in the untreated NEC group. Intestinal IL-10 levels did not differ between NEC + FLLL32 and untreated NEC groups (data not shown).

**Discussion**

NEC is a devastating disease characterized by inflammation and injury to the small intestine. Despite early and aggressive treatment, NEC can quickly progress to frank bowel necrosis and death.5,33 Although the pathogenesis of NEC is still unclear, observations suggest a complex interplay between prematurity, formula feeding, hypoxia, and altered bacterial colonization.5,34,35 In premature infants, developmental immaturity of mucosal barrier and increased expression of TLR4 on the surface of the intestinal epithelium render the gut highly reactive and susceptible to injury from various stimuli.7 This leads to an exaggerated proinflammatory cytokine release, leukocyte infiltration, altered epithelial barrier, intestinal necrosis, and bacterial translocation across the lumen.36,37

FLLL32 is a curcumin analog with improved solubility and bioavailability compared to the parent product.22 Although FLLL32 has been extensively used in cancer models,22,38,39 its use in inflammation, specifically in NEC, has not been explored. Our results demonstrate that FLLL32 given orally at 25 mg/kg is well tolerated in neonatal mice pups. We also show that similar to curcumin,16 prophylactic administration of FLLL32 reduces the incidence and severity of NEC in DK mode. FLLL32 also preserved intestinal permeability and reduced intestinal proinflammatory cytokines, both of which play important roles in the pathogenesis of NEC.3,6,9,29-31 Although we did not perform a comparison of FLLL32 and curcumin in NEC, our results show that FLLL32 was superior to curcumin in preserving intestinal barrier function in vitro. The protective mechanism of FLLL32 could be through STAT3 inhibition, which has been shown to modulate PAF-induced TLR4 expression in intestinal epithelial cells in vivo.40

**Conclusion**

Oral FLLL32 decreases intestinal inflammation and injury in a DK NEC model. Further studies are needed to better understand the mechanisms underlying its protective effects.
Acknowledgments

We would like to acknowledge Randle Gallucci, PhD, and Kathryn Burge, PhD, in helping with manuscript editing. This paper was presented in part at the Pediatric Academic Society Meeting, April 28, 2015.41

Disclosure

The authors report no conflicts of interest in this work.

References

42. submit your manuscript | www.dovepress.com
43. For personal use only.
44. Dinh Dinh Huy, Tran Thanh Hai. *Journal of Inflammation Research* 2017:10
Journal of Inflammation Research

Publish your work in this journal

The Journal of Inflammation Research is an international, peer-reviewed open access journal that welcomes laboratory and clinical findings on the molecular basis, cell biology and pharmacology of inflammation including original research, reviews, symposium reports, hypothesis formation and commentaries on: acute/chronic inflammation; mediators of inflammation; cellular processes; molecular mechanisms; pharmacology and novel anti-inflammatory drugs; clinical conditions involving inflammation. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/journal-of-inflammation-research-journal